메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Globally Significant Opportunity Emerges as Remplir™ is used in Nerve-Sparing Prostate Cancer Surgery

Potential to reduce the risk of erectile dysfunction and urinary incontinence PERTH, Australia, Sept. 16, 2025 -- Regenerative medicine company Orthocell Limited (ASX:OCC, "Orthocell" or the "Company") is pleased to announce its flagship nerve repair device, Remplir, has been introduced to Urologists in Australia for use in nerve-sparing Robotic-Assisted Radical Prostatectomies (RARP). Remplir has been used in approximately 40 surgical cases to assist in improving recovery of erectile function and urinary continence post-surgery. Orthocell is collating clinic
- 김갑성 기자
- 2025-09-16 12:13
ANYTIME FITNESS CELEBRATES 80TH CLUB MILESTONE IN MALAYSIA, UNVEILS STRATEGIC PARTNERSHIP WITH MINISTRY OF YOUTH AND SPORTS

CYBERJAYA, Malaysia, Sept. 16, 2025 -- Anytime Fitness, the world's largest and fastest-growing fitness franchise, proudly marks a major milestone with the opening of its 80th club in Malaysia, located at Neocyber, Wisma Mustapha Kamal in Cyberjaya — a hub of innovation and modern living. This milestone coincides with the launch of a strategic collaboration with the Ministry of Youth and Sports Malaysia (KBS), reinforcing a shared mission to build a healthier, more active nation. The partnership will support national wellness campaigns and drive community-based initiatives across all l
- 노기식 기자
- 2025-09-16 11:23
Akeso's Ligufalimab (CD47 mAb) Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia (AML)

HONG KONG, Sept. 16, 2025 -- Akeso Inc. (9926.HK) today announced that its proprietary next-generation humanized IgG4 monoclonal antibody targeting CD47, ligufalimab (AK117), has been granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of acute myeloid leukemia (AML). The Orphan Drug Designation is a program established by the FDA to incentivize the development of therapies for rare diseases. Drugs with this designation benefit from comprehensive FDA guidance during development, tax incentives, and up to seven years of market exclusivity upon approval. Akeso
- 김갑성 기자
- 2025-09-16 10:27
Chulalongkorn Bariatric and Metabolic Institute (Chula BMI), a One-Stop Service Center for Holistic Obesity Treatment

BANGKOK, Sept. 16, 2025 -- Say goodbye to obesity with the Chulalongkorn Bariatric and Metabolic Institute (Chula BMI)—King Chulalongkorn Memorial Hospital's one-stop center for comprehensive, holistic obesity care. A team of doctors and multidisciplinary specialists, including experts in medicine, surgery, nutrition, and behavioral therapy, is now ready to provide patients with guidance on preventing obesity before it's too late. Are you obese? Find out from the BMI formula. Body mass index (BMI) = body weight (kg)/height (m) 2 If your answer is between
- 김갑성 기자
- 2025-09-16 10:00
Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the 34th EADV Congress 2025

SAN FRANCISCO and SUZHOU, China, Sept. 16, 2025 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announces that it will present multiple research results at the 34th European Academy of Dermatology and Venereology (EADV) Congress 2025 in Paris, France from September 17-20. Specifically, post hoc analysis of Phase 2 and Phase 3 clinical studies of IBI11
- 김갑성 기자
- 2025-09-16 09:00
Baxter Launches HEMOPATCH Sealing Hemostat in New Zealand, a Room-Temperature Collagen Pad Approved for Hemostasis and Sealing

DEERFIELD, Ill., Sept. 15, 2025 -- Over the past two decades, surgical techniques have increasingly shifted toward minimally invasive approaches, requiring adapted workflows and skillsets. At the same time, patient complexity has grown, calling for tailored strategies to support safe and effective care in the operating room. After its global launch in Europe, Baxter has introduced Hemopatch Sealing Hemostat in New Zealand. Hemopatch Sealing Hemostat is a room-temperature storage collagen pad designed for hemostasis and sealing in both open and minimally invasive surgical proced
- 김갑성 기자
- 2025-09-16 06:00
LBB Specialties and Imerys Form Specialty Distribution Partnership in North America

NORWALK, Conn., Sept. 16, 2025 -- LBB Specialties (LBBS), a leader in specialty chemicals and ingredient distribution in North America, is pleased to announce a new partnership with Imerys, a world leader in mineral-based specialties for industry. This agreement names LBBS as the preferred distributor for Imerys ImerCare® product line in Personal Care, and minerals serving the Food & Nutrition markets. The partnership extends across the United States, Canada, and Puerto Rico. Through this partnership, LBBS will support customers in the Personal Care, Life Sciences, and
- 김갑성 기자
- 2025-09-16 01:00
Glac Biotech Secures U.S. Food and Drug Administration GRAS Approval for Probiotic Strain CP-9

TAIPEI, Sept. 15, 2025 -- Glac Biotech, a Taiwan-based developer of probiotics and postbiotics, announced that its core probiotic strain CP-9 (Bifidobacterium lactis CCTCC M 2014588) has been approved with Generally Recognized as Safe (GRAS) status by the U.S. Food and Drug Administration (FDA). With this notification, Glac Biotech becomes the only probiotic raw material manufacturer in Taiwan to hold multiple FDA GRAS approval, following the recognition of Lactobacillus rhamnosus MP108 in 2023. Approval Highlights CP-9's Safety and Quality According to the FDA fi
- 김갑성 기자
- 2025-09-15 22:00
Glac Biotech、プロバイオティクス株CP-9で米国食品医薬品局のGRAS認証を取得

[ 메디채널 김갑성 기자 ] 台北、2025年9月15日 -- Glac Biotechは、台湾を拠点とするプロバイオティクスおよびポストバイオティクスの開発企業であり、同社の中核となるプロバイオティクス株CP-9（Bifidobacterium lactis CCTCC M 2014588）が米国食品医薬品局（FDA）より「一般に安全と認められる（GRAS）」認証を取得したと発表しました。この通知により、Glac Biotechは2023年にLactobacillus rhamnosus MP108が認定されたことに続き、台湾でFDAのGRAS認証を複数有する唯一のプロバイオティクス原料メーカーとなります。 CP-9の安全性と品質を裏付ける認証 FDAへの申請によると、CP-9は1食当たり最大10⁹コロニー形成単位（CFU）の使用が認可されており、以下のような幅広い食品および飲料製品に利用することができます。スポーツドリンク・エナジードリンク強化水ボトル入り茶飲料シリアル乳製品および非乳製品栄養バーキャンディフルーツジュース大豆・植物由来のたんぱく質製品乳児用食品新たに認証されたCP-9は、2023年のニュートライング
- 김갑성 기자
- 2025-09-15 22:00
글락바이오텍 프로바이오틱 균주 CP-9, FDA GRAS 승인 획득

[ 메디채널 김갑성 기자 ] 타이베이 2025년 9월 15일 -- 대만 기업 글락 바이오텍(Glac Biotech)이 개발한 프로바이오틱스 균주 CP-9(비피도박테리움 락티스 CCTCC M 2014588)가 FDA 승인을 획득하였다. 글락 바이오텍은 프로바이오틱스와 포스트바이오텍스 개발업체로 이번 승인 등급은 일반적으로 안전하다고 인정되는 제품(GRAS)이다. 글락 바이오텍은 이번 승인으로 2023년 락토바실러스 람노서스 MP108(Lactobacillus rhamnosus MP108) 승인에 이어 대만 프로바이오틱스 원료 제조사 중에서는 유일하게 FDA GRAS 승인을 복수로 받은 업체가 되었다. 승인은 CP-9의 안전성과 품질을 인정한 것 FDA 신고서에 따르면 CP-9는 다음과 같이 여러 식음료 제품에 1회분 당 10⁹ 콜로니 형성 단위(CFU)까지 사용 가능하다. 스포츠 및 에너지 음료 강화수 병에 담긴 차 시리얼 유제품과 비유제품 뉴트리션 바 캔디 과일 주스 콩 및 식물성 단백질 제품 유아식 이번에 승인받은 CP-9는 2023년
- 김갑성 기자
- 2025-09-15 22:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-09-16_TUE

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 16일 14시 00분